insights_auto
Why is CVM down ၂၅.၄၁%?
Dive Deeperchevron_right
CVM:NYSEAMERICAN
CEL-SCI Corp
၁.၃၈ US$
arrow_downward
-၂၅.၄၁%(-၀.၄၇) 1D
၁.၃၉ US$
arrow_upward
+၀.၇၂% (+၀.၀၁၀၀)todayPre-market
Closed: နို ၁၈, GMT-၅ ၁၆:၀၀:၀၀ · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for CVM...
Open
၁.၇၀ US$
High
၁.၇၁ US$
Low
၁.၃၄ US$
Mkt. cap
၂.၄၃ ကုဋေ
Avg. vol.
၂.၃၆ သိန်း
Volume
၈.၀၇ ထောင်
52-wk high
၇.၈၀ US$
52-wk low
၀.၈၉ US$
EPS
-၂.၆၈ US$
Beta
၀.၆၂
Shares outstanding
၁.၇၆ ကုဋေ
No. of employees
၄၃
Open
၁.၇၀ US$
High
၁.၇၁ US$
Low
၁.၃၄ US$
Mkt. cap
၂.၄၃ ကုဋေ
Avg. vol.
၂.၃၆ သိန်း
Volume
၈.၀၇ ထောင်
52-wk high
၇.၈၀ US$
52-wk low
၀.၈၉ US$
EPS
-၂.၆၈ US$
Beta
၀.၆၂
Shares outstanding
၁.၇၆ ကုဋေ
No. of employees
၄၃
News stories
From web sources and news partners
Business Insider
·
ပြီးခဲ့သည့် ၁၉ မိနစ်
Why Morgan Stanley Says the S&P 500 Is Poised to Jump 18%
The Motley Fool
·
ပြီးခဲ့သည့် ၃၇ မိနစ်
Is Investing in an S&P 500 ETF Really Enough? Here's My Honest Take.
Benzinga
·
ပြီးခဲ့သည့် ၃၀ မိနစ်
Stock Market Today: Dow, S&P 500 Futures Rise as Wall Street Awaits Anthropic's Listing— PANW, NTES, SLS in Focus
FOREX.com
·
ပြီးခဲ့သည့် ၅ နာရီ
S&P 500 Grasps At Support as Surging Hike Odds, Treasury Yields Threaten Larger Turn
Profile
Cel-Sci Corporation, is a biotechnology company that tests drugs for the treatment of cancer, autoimmune and infectious diseases through the research and development of immunotherapy products.
Cel-Sci's main product is the drug Multikine, an immunotherapeutic agent designed to fight cancer by stimulating the body's immune system. Multikine is currently in Phase III of Clinical Trials with the Food and Drug Administration. Multikine has also been referred to as Leukocyte Interleukin Injection. Multikine was in Phase II testing of patients with head and neck cancer in the early 2000s, in which it demonstrated tumor-reducing ability. In January 2007, the US cleared the Phase 3 trial and Multikine was designated as an orphan drug by the FDA for neoadjuvant therapy of patients with squamous cell carcinoma of the head and neck. A total of 928 patients were enrolled in the head and neck cancer drug trial at that time. Subsequently, in June 2021, the company announced that the study missed its primary endpoint. Wikipedia
About CEL-SCI Corp
CEO-
Employees၄၃
Foundedမတ် ၁၉၈၃
Headquartersဗီယင်နာ, ဗာဂျီးနီးယားပြည်နယ်, ယူနိုက်တက်စတိတ်
SectorHealth Care
Industry-
Websitecel-sci.com